Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes

Cancer Biology and Therapy

Volumn 2, Issue 1, 2003, Pages 103-108

  Jiang, Guanchao ^a   Yang, Fan ^a   Li, Marilyn ^a   Weissbecker, Karen ^a   Price, Sherrie ^a   Kim, K C ^a   La Russa, Vincent F ^a   Safah, Hana ^a   Ehrlich, Melanie ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

BCR ABL; Chronic phase CML; DNA methylation; Imatinib; RT PCR; STI571

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PYRIMIDINE DERIVATIVE;

ARTICLE; BONE MARROW CELL; CANCER STEM CELL; CHROMOSOME 22; CHROMOSOME 9; CHROMOSOME ABERRATION; CHRONIC MYELOID LEUKEMIA; CLONOGENIC ASSAY; DNA METHYLATION; DRUG EFFECT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE TRANSLOCATION; GENETIC TRANSCRIPTION; GENETICS; HEMATOPOIETIC STEM CELL; HUMAN; KARYOTYPING; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BONE MARROW CELLS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 22; CHROMOSOMES, HUMAN, PAIR 9; COLONY-FORMING UNITS ASSAY; DNA METHYLATION; FUSION PROTEINS, BCR-ABL; HEMATOPOIETIC STEM CELLS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; LEUKEMIA, MYELOID, CHRONIC; PROMOTER REGIONS (GENETICS); PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; TRANSLOCATION, GENETIC; TUMOR STEM CELLS;

EID: 0038498328     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rowley JD. The Philadelphia chromosome translocation. A paradigm for understanding leukemia. Cancer 1990; 65:2178-84.
2. Sawyers CL, Druker B. Tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J Sci Am 1999; 5:63-9. (Pubitemid 29169292)
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996; 2:561-6.
4. Kantarjian HM, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346:645.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031-7. (Pubitemid 32267972)
6. Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2:117.
7. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, Lai JL, Philippe N, Facon T, et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 2002; 100:1014-8. (Pubitemid 34832631)
8. Deininger MW, Goldman JM, Lydon N, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 1997; 90:3691-8. (Pubitemid 27473440)
9. Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ. Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on line-age-committed and primitive chronic myelogenous leukemia progenitors. Cancer Chemother. Pharmacol 1999; 44:433-8. (Pubitemid 29455591)
10. Waller CF, Ali M, Heinzinger M, Lange W. Growth inhibition of Ph+ progenitor cells from CML patients using the tyrosine kinase inhibitor CGP57148B. Anticancer Res 2000; 20:809-14. (Pubitemid 30240637)
11. Jiang XY, Trujillo JM, Dao D, Liang JC. Studies of BCR and ABL gene rearrangements in chronic myelogenous leukemia patients by conventional and pulsed-field gel electrophoresis using gel inserts. Cancer Genet. Cytogenet. 1989; 42:287-94.
12. Sun B, Jiang G, Zaydan MA, La Russa VF, Safah H, Ehrlich M. ABL1 promoter methylation can exist independently of BCR-ABL transcription in chronic myeloid leukemia hematopoietic progenitors. Cancer Res 2001; 61:6931-7. (Pubitemid 32896521)
13. Nguyen TT, Mohrbacher AF, Tsai YC, Groffen J, Heisterkamp N, Nichols PW, et al. Quantitative measure of c-ABL and p15 methylation in chronic myelogenous leukemia: biological implications. Blood 2000; 95:2990-2. (Pubitemid 30235914)
14. Issa JP, Kantarjian H, Mohan A, O'Brien S, Cortes J, Pierce S, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 1999; 93:2075-80. (Pubitemid 29128511)
15. Ben-Yehuda D, Krichevsky S, Rachmilewitz EA, Avraham A, Palumbo GA, Frassoni F, et al. Molecular follow-up of disease progression and interferon therapy in chronic myelocytic leukemia. Blood 1997; 90:4918-23. (Pubitemid 28007206)
16. Asimakopoulos FA, Shteper PJ, Krichevsky S, Fibach E, Polliack A, Rachmilewitz E, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999; 94:2452-60. (Pubitemid 29467694)
17. Sun J, Zhao J, Schwartz MA, Wang JY, Wiedmer T, Sims PJ. c-Abl tyrosine kinase binds and phosphorylates phospholipid scramblase 1. J. Biol. Chem. 2001; 276:28984-90.
18. Zion M, Ben-Yehuda D, Avraham A, Cohen O, Wetzler M, Melloul D, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc. Natl. Acad. Sci. USA 1994; 91:10722-6.
19. Diamond J, Goldman JM, Melo JV. BCR-ABL, ABL-BCR, and ABL genes are all expressed in individual granulocyte- macrophage colony-forming unit colonies derived from blood of patients with chronic myeloid leukemia. Blood 1995; 85:2171-5.
20. Thijsen SF, Schuurhuis GJ, van Oostveen JW, Theijsmeijer AP, Langenhuijsen MM, Ossenkoppele GJ. Molecular analysis of hematopoietic colonies derived from chronic myeloid leukemia patients: interphase fluorescence in situ hybridization compared with RT-PCR. Leukemia 1997; 11:301-5. (Pubitemid 27085178)
21. Savoldo B, Sammarelli G, Dotti G, Garau D, Regazzi E, Cilloni D, et al. Reverse transcription polymerase chain reaction is a reliable assay for detecting leukemic colonies generated by chronic myelogenous leukemia cells. Leukemia 1998; 12:434-40. (Pubitemid 28138230)
22. Hochhaus A, Lin F, Reiter A, Skladny H, Mason PJ, van Rhee F, et al. Quantification of residual disease in chronic myelogenous leukemia patients on interferon-alpha therapy by competitive polymerase chain reaction. Blood 1996; 87:1549-55. (Pubitemid 26056920)
23. Buchdunger E. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 1999; 295:139-45.
24. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96:925-32. (Pubitemid 30618049)
25. Pierce A, Spooncer E, Ainsworth S, Whetton AD. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene 2002; 21:3068-75. (Pubitemid 34522907)
26. Baylin SB, Herman JG. Epigenetics and Loss of Gene Function in Cancer. In: Ehrlich M, ed. DNA Alterations in Cancer. Natick: Eaton Publishing, 2000:293-309.
27. Kabarowski JH, Witte ON. Consequences of BCR-ABL expression within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells 2000; 18:399-408.
28. Matioli GT. BCR-ABL insufficiency for the transformation of human stem cells into CML. Med Hypotheses 2002; 59:588-9. (Pubitemid 35216798)
29. Keating A, Wang XH, Laraya P. Variable transcription of BCR-ABL by Ph+ cells arising from hematopoietic progenitors in chronic myeloid leukemia. Blood 1994; 83:1744-9. (Pubitemid 24107895)
30. Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ. Efficacy of STI571, an ABL tyrosine kinase inhibitor, in conjunction with other antileukemic agents against BCR-ABL-positive cells. Blood 2000; 96:3195-9.